Aptar Pharma QuickStart Injectables wins Industry Innovation Award at Pharmapack 2019

  • Aptar Pharma

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that their recently-launched QuickStart™ for Injectables has won Best Innovation in Packaging Material & Component category at the 2019 Pharmapack Awards in Paris, France.

QuickStart Injectables is a sterile, Ready-To-Use (RTU) drug development offering designed specifically to accelerate the development time for start-ups and early stage development, R&D, biotechs, and university research organizations.

Aptar Pharma launched this highly-innovative injectable development package in October 2018 at CPhI Worldwide in Madrid.

Aptar Pharma also announced at Pharmapack 2019 that the award-winning QuickStart development package is now available for online purchase via the Aptar Pharma website utilizing a convenient, easy-to-use configurator, further simplifying access for research scientists and drug developers with a click of a button. QuickStart comes with several other key scientific benefits.

QuickStart Injectables provides a one-stop packaging solution, which allows developers to focus on their science and chemistry. QuickStart arrives RTU to the point of use, which reduces the number of human/product interactions while at the same time optimizing manufacturing productivity, as the vials, stoppers, and caps can be used immediately upon receipt and directly introduced into restricted access barrier systems (RABS) or isolators.

QuickStart Injectables comes with gamma-sterilized stoppers and push-off caps, and ETO-sterilized vials to provide customers with better quality, real flexibility, convenience, and speed. The package, complete with glass vials from Schott, elastomeric stoppers from Aptar Pharma and push-off caps from EMA Pharmaceuticals, provides everything needed for the small-volume filling of high value formulations.

QuickStart Injectables is also able to cater to different sizes and configurations of vials, stoppers, and caps. The offering also includes all of the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components, which serves to proactively address regulators’ needs and accelerate approval.

Bas Van Buijtenen, President of the Aptar Pharma Injectables Division, comments, “We are delighted that QuickStart Injectables has won ‘Best Innovation in Packaging Material & Component’ at this year’s Pharmapack Awards. With QuickStart, we are enabling small scale sterile fills for innovative drug companies. Because we offer a small scale packaging solution identical to what will be used for large scale fills, these innovators gain reliability and time in their drug development pipeline.”

Adam Shain, Aptar Pharma’s Director, Global Business Development – Injectables, adds “Winning the Pharmapack innovation award is a recognition of an industry need for fast development solutions. QuickStart Injectables is all about convenience, speed, and quality by enabling companies to have a quick and positive development experience. This need for speed and convenience is what drove us to make QuickStart available online, because we recognized that when developers are starting out, it is not always obvious how to procure the packaging they require.

The success of QuickStart Injectables demonstrates a true team effort bringing together the best solutions from Schott, Aptar Pharma, and EMA Pharmaceuticals. Together, we are able to deliver a robust and easy-to-use solution, which lets our pharmaceutical partners focus on the drug product, while we take care of the packaging. I look forward to the continued success of Aptar Pharma QuickStart”.

See also

Aptar’s Nasal Unidose Device approved by US FDA

Aptar’s Nasal Unidose Device approved by US FDA

AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

Aptar Pharmas Freepod nasal spray device with GlaxoSmithKlines Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

Aptar Pharma launches PureHale, a new portable and ready-to-use upper respiratory drug delivery solution

Aptar Pharma launches PureHale, a new portable and ready-to-use upper respiratory drug delivery solution

Aptar Pharma, a leading drug delivery systems provider, continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.

Join Aptar Pharmas live webinar Good medicine: Solutions for sensitive injectable formulations

Join Aptar Pharma's live webinar "Good medicine: Solutions for sensitive injectable formulations"

Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk. Taking place on October 24, 2018, at 15.00 GMT, the webinar, entitled “Good Medicine: Solutions for Sensitive Injectable Formulations” will demonstrate how high quality film coated components meet compliance expectations while maintaining safety of supply for the drug product..

New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced it will be hosting a live, complimentary webinar titled “Optimizing Patient Adherence and Compliance in Eye Care” on November 21 at 11AM EST. The webinar will offer expert insight from Matthias Birkhoff, Vice President Business Development at Aptar Pharma, and Dr. Degenhard Marx, Director Scientific Affairs within the Aptar Pharma Consumer Health Care Division.

Aptar Pharmas electronic lockout device approved by EMA

Aptar Pharma's electronic lockout device approved by EMA

Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.

Aptar Pharmas preservative free multi-dose ophthalmic squeeze dispenser launches in the U.S.

Aptar Pharma's preservative free multi-dose ophthalmic squeeze dispenser launches in the U.S.

Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma's innovative preservative free multi-dose Ophthalmic Squeeze Dispenser (OSD). This is the first preservative free multi-dose eye drop featuring Aptar Pharma's OSD in the United States.

The tenth anniversary of RDD Europe: A great success for the international Respiratory Drug Delivery community

The tenth anniversary of RDD Europe: A great success for the international Respiratory Drug Delivery community

RDD® Europe 2015 hosted 450 pulmonary and nasal drug delivery experts from 31 countries at its latest conference in Antibes, France, demonstrating once again that it is the "must attend" European event in pulmonary and nasal drug delivery. RDD Europe is a prestigious event, jointly organized by RDD Online and Aptar Pharma, bringing together scientists, clinicians, business professionals and regulators to further research, development, clinical evaluation and marketing of current and new drugs delivered through the lungs or nose.

  • Isabel Thomas
  • Product Info
  • English
  • Created 07 Feb 2019
  • Modified 12 Apr 2019
  • Hits 229